Ophthalmic Patents (Class 514/912)

Cross-Reference Art Collections

Glaucoma (Class 514/913)
Inflammation (Class 514/914)
Wetting agent (Class 514/915)
  • Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
    Patent number: 5602143
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having guanylate cyclase inhibition activity. Examples of guanylate cyclase inhibitors utilized in the pharmaceutical composition and method of treatment are: ##STR1## and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: February 11, 1997
    Assignee: Allergan
    Inventor: Achim H. Krauss
  • Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use
    Patent number: 5599534
    Abstract: Reversibly gel-forming compositions for sustained delivery of bio-affecting substances are disclosed. The compositions exhibit significant changes in viscosity in response to changes in pH. The compositions contain relatively low concentrations of a stable combination of at least one pH-responsive gelling polymer and at least one other thermally nonresponsive polymer. The compositions are preferably formulated to include one or more therapeutic or diagnostic agents for administration as a liquid that will gel in situ or for topical application as a pre-formed gel.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: February 4, 1997
    Assignee: University of Nebraska
    Inventors: Kenneth J. Himmelstein, Cara L. Baustian
  • Methods for the cyto-protection of the trabecular meshwork
    Patent number: 5599535
    Abstract: The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury to the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity, or prevent, glaucoma.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 4, 1997
    Assignee: Regents of the University of California
    Inventors: Jon R. Polansky, Ernest Bloom, Donald J. Fauss
  • Diclofenac and tobramycin formulations for ophthalmic and otic topicaluse
    Patent number: 5597560
    Abstract: This invention includes a pharmaceutically acceptable formulation of Diclofenac, Tobramycin, a solubility agent and, optionally, excipients, tonicifiers, buffers, viscosity modifying agents, preservatives, and chelating agents, at a pH from greater than 7.0 to about 9. The invention also discloses the use of this pharmaceutically acceptable formulation of an antibiotic and NSAIDs to treat eye and ear conditions accompanied by infection and inflammation.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: January 28, 1997
    Assignee: Laboratorios Cusi, S.A.
    Inventors: Michael V. W. Bergamini, Jose A. Vallet Mas, Gemma T. Cabello, Antonio L. Cabrera
  • Method for the treatment of macular degeneration
    Patent number: 5596011
    Abstract: Macular degeneration is an age-related eye disease for which there is no known treatment to date that has been shown to be effective at treating or preventing the onset or progression of the disease. Current treatment of non-exudative (dry form) macular degeneration is limited to early diagnosis and careful followup, while symptomatic treatment of exudative (wet form) macular degeneration includes laser photocoagulation therapy, surgery, low dose radiation (teletherapy), and anti-oxidant or anti-inflammatory therapies. The present invention relates to a new method for treating or preventing the onset or progression of macular degeneration, comprising periodic administration of a glutathione (GSH) enhancing agent alone or in conjunction with at least one of an anti-oxidant or an anti-inflammatory therapy, and possibly in addition to one or more of the symptomatic treatments mentioned above.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: January 21, 1997
    Inventors: Karen M. Repine, John E. Repine
  • Ophthalmic composition for treating dry eye
    Patent number: 5595764
    Abstract: An ophthalmologic composition therapeutic in the treatment of dry eye syndrome is disclosed. The composition is comprised of a minimally soluble salt of calcium that has been finely divided into particles having a mean diameter of 10 to 60 microns. The calcium salt particles are suspended within a pharmacologically acceptable carrier such as petrolatum or physiological saline. The composition is delivered to the ocular surface in an amount and for a time sufficient to alleviate the symptoms of dry eye.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: January 21, 1997
    Assignee: DEO Corporation
    Inventor: Donald L. Mackeen
  • Method of making thermoreversible polyoxyalkylene gels
    Patent number: 5593683
    Abstract: Compositions based upon aqueous gels for medical application, comprising polyoxyalkylene copolymers. Such gels which are isotonic, iso-osmotic, pH balanced, thermo-reversible gels are ideal vehicles for drug or diagnostic agent delivery.
    Type: Grant
    Filed: March 3, 1994
    Date of Patent: January 14, 1997
    Assignee: MDV Technologies, Inc.
    Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
  • Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
    Patent number: 5591773
    Abstract: A method of inhibiting the formation of a cataract in an eye by contacting the eye with a compound having the structure: ##STR1## is described. Also described is a method of inhibiting the progression of cataract formation in an eye. Methods comprising administering a pharmaceutical composition comprising the above compound to inhibit the formation of a cataract in the eye of a subject and to inhibit progression of cataract formation in the eye of a subject are also described. The above compound also prevents diseases resulting from oxidative stress, including diseases comprising tumor formation resulting from oxidative stress, and also inhibits the progression of diseases resulting from oxidative stress. The above compound may furthermore be used to treat an HIV infection when combined in a pharmaceutical composition with a substance which inhibits HIV replication.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: January 7, 1997
    Assignees: The Trustees of Columbia University in the City of New York, New York University
    Inventors: Dezider Grunberger, Krystyna Frenkel
  • Medical uses of in situ formed gels
    Patent number: 5587175
    Abstract: Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: December 24, 1996
    Assignee: MDV Technologies, Inc.
    Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
  • Nonirritating nonionic tissue cleaning method
    Patent number: 5585406
    Abstract: A nonirritating, nonionic detergent surfactant composition suitable for application to and cleaning of sensitive tissue, including periocular and ocular tissue, having a low cytotoxicity and high cleaning ability includes a principal nonionic surfactant and at least one auxiliary nonionic surfactant present in the surfactant composition in sufficient amounts to increase the cleaning ability of the principal non-ionic surfactant.
    Type: Grant
    Filed: June 9, 1993
    Date of Patent: December 17, 1996
    Assignee: Allergan, Inc.
    Inventors: Shulin Ding, Thao T. Tran
  • Suppressant of corneal subepithelial clouding
    Patent number: 5585354
    Abstract: Suppressant of corneal subepithelial clouding, in particular, one that is capable of effective suppression of corneal subepithelial clouding which can potentially develop after superficial keratectomy with an excimer laser. The suppressant contains gamma-interferon or variants thereof as an active ingredient and it is formulated in dosage forms suitable for topical administration. In may be commonly applied as an eye drop or an ophthalmic ointment after formulation with additives such as isotonizers, buffer agents, stabilizers, antiseptics, pH modifiers and ophthalmic ointment bases.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: December 17, 1996
    Assignee: Suntory Limited
    Inventors: Yuichi Ohashi, Keizo Takahashi
  • Hyaluronic acid-urea pharmaceutical compositions and uses
    Patent number: 5583120
    Abstract: This invention includes a pharmaceutical composition including a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically salt thereof. The invention also includes a method of treating disease of the cutis which includes applying to cutis tissues in need of such treatment a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically acceptable salt thereof, said disease having symptoms selected from the group consisting of inflammation, erythema, edema, papules, vesicles, macules, pustules, scaling, cracking, crusting, and lesions.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 10, 1996
    Assignee: Patent Biopharmaceutics, Inc.
    Inventor: Damian J. Gallina
  • 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
    Patent number: 5583150
    Abstract: The use of 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for treating ocular diseases with immune etiology is disclosed.
    Type: Grant
    Filed: October 4, 1994
    Date of Patent: December 10, 1996
    Assignee: Alcon Laboratories, Inc.
    Inventors: Stella M. Robertson, Laura S. Lang
  • Hyaluronic acid-urea pharmaceutical compositions and uses
    Patent number: 5583119
    Abstract: This invention includes a pharmaceutical composition including a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically salt thereof. The invention also includes a method of treating disease of the cutis which includes applying to cutis tissues in need of such treatment a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically acceptable salt thereof, said disease having symptoms selected from the group consisting of inflammation, erythema, edema, papules, vesicles, macules, pustules, scaling, cracking, crusting, and lesions.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 10, 1996
    Assignee: Patent Biopharmaceutics, Inc.
    Inventor: Damian J. Gallina
  • Method of treating an anorectal disease using hyaluronic acid-urea pharmaceutical compositions
    Patent number: 5583118
    Abstract: This invention includes a pharmaceutical composition including a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically salt thereof. The invention also includes a method of treating disease of the cutis which includes applying to cutis tissues in need of such treatment a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically acceptable salt thereof, said disease having symptoms selected from the group consisting of inflammation, erythema, edema, papules, vesicles, macules, pustules, scaling, cracking, crusting, and lesions.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 10, 1996
    Assignee: Patent Biopharmaceutics, Inc.
    Inventor: Damian J. Gallina
  • Dry eye treatment process and solution
    Patent number: 5578586
    Abstract: A method and composition for reducing evaporation of an aqueous layer from the surface of the eye. The method comprises applying an admixture of a charged phospholipid and a non-polar oil over the eye, preferably in the form of a meta-stable oil in water emulsion in a dosage not exceeding 100 microliters.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: November 26, 1996
    Assignee: Ocular Research of Boston, Inc.
    Inventors: Thomas Glonek, Jack V. Greiner, Donald R. Korb
  • Method of preserving ophthalmic solutions and compositions therefor
    Patent number: 5576028
    Abstract: A preservative for ophthalmic solutions having an active ingredient is provided, having a hydrogen peroxide content of about 0.001% to about 0.10% by weight; and diethylene triamine penta(methylene phosphonic acid) or a physiologically compatible salt thereof, present at about 0.002% to 0.03% by weight and/or 0.005% to about 0.20% by weight of 1-hydroxyethylidene-1,1-diphosphonic acid, or physiologically acceptable salt thereof.
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: November 19, 1996
    Assignee: Ciba Geigy Corporation
    Inventors: Stephen M. Martin, Fu-Pao Tsao
  • Stable highly concentrated formulations of fluorescein derivatives
    Patent number: 5573773
    Abstract: The present invention relates to stable highly concentrated formulations of specific fluorescein derivatives, to the preparation of said formulations and the use thereof, especially for the photodynamic therapy of secondary cataract.The invention principally relates to an aqueous solution comprising a fluorescein diester, preferably a fluorescein di-lower alkyl ester, most preferably fluorescein diacetate, and a partially etherified .beta.-cyclodextrin the ether substituents of which are hydroxyethyl, hydroxypropyl or dihydroxypropyl groups, some of which ether substituents may be methyl or ethyl groups, said .beta.-cyclodextrin ether having a water-solubility of more than 1.8 g in 100 ml of water, preferably hydroxy-.beta.-cyclodextrin.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: November 12, 1996
    Assignee: Ciba Geigy Corporation
    Inventors: Gyoergy L. Kis, Ernst D. Wachsmuth
  • Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
    Patent number: 5573758
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having potassium channel blocking activity. Examples of potassium channel blockers utilized in the pharmaceutical composition and method of treatment are quinine, tremogenic indole alkaloids, such as Penitrem A and paspalicine, and insect toxins such as charybdotoxin and iberiotoxin.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 12, 1996
    Assignee: Allergan
    Inventors: Joseph S. Adorante, Elizabeth WoldeMussie, Guadalupe Ruiz
  • Adamantyl-substituted polycyclic acetylene compounds and pharmaceutical/cosmetic compositions comprised thereof
    Patent number: 5574036
    Abstract: Novel pharmaceutically/cosmetically-active adamantyl-substituted polycyclic acetylene compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(f): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: November 12, 1996
    Assignee: Centre International de Recherches Dermatologiques Galderma
    Inventors: Jean-Michel Bernardon, Bruno Charpenter
  • Pharmacological treatment of ocular development
    Patent number: 5571823
    Abstract: A method of controlling the abnormal postnatal growth of the eye of a maturing animal which comprises the ocular administration of therapeutically effective amounts of a dopamine antagonist.
    Type: Grant
    Filed: June 22, 1993
    Date of Patent: November 5, 1996
    Assignees: The Trustees of the University of Pennsylvania, Emory University
    Inventors: Richard A. Stone, Alan M. Laties, Paul M. Iuvone
  • Gaba-ergic modulation of eye growth
    Patent number: 5567731
    Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a gamma aminobutyric acid antagonist relatively selective for GABA.sub.B receptors in the cells of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is 2-OH saclofen.
    Type: Grant
    Filed: September 27, 1994
    Date of Patent: October 22, 1996
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Alan M. Laties, Richard A. Stone
  • Method for the healing of wounds caused by corneal injury
    Patent number: 5561109
    Abstract: A method for the healing of wounds caused by corneal injury, which includes administering to a mammalian patient in need thereof an effective wound healing amount of lactoferrin, lactoperoxidase or a combination of lactoferrin and lactoperoxidase as active ingredients, either alone or in admixture with at least one excipient.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: October 1, 1996
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Shiro Mita, Mitsushi Hikida, Michel F. Degre
  • Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
    Patent number: 5559151
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having chloride channel blocking activity. Examples of chloride channel blockers utilized in the pharmaceutical composition and method of treatment are: ##STR1## wherein R is hydrogen or a pharmaceutically-acceptable cation, e.g. an alkali or alkaline earth metal, or a quaternary amine; or R represents a ester-forming moiety, e.g. a lower alkyl radical, having up to six carbon atoms, that may be derived from a lower alkanol.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: September 24, 1996
    Assignee: Allergan
    Inventors: Joseph S. Adorante, Elizabeth WoldeMussie, Guadalupe Ruiz
  • Ophthalmic compositions containing vitamin E or ester thereof as an active ingredient
    Patent number: 5559157
    Abstract: This invention relates to novel aqueous ophthalmic compositions containing vitamin E or ester thereof as an active ingredient, sorbic acid or salts thereof as a preservative, and surfactant. The composition of this invention is useful for treatment of various eye diseases, especially for cataract.
    Type: Grant
    Filed: May 19, 1993
    Date of Patent: September 24, 1996
    Assignee: Santen Pharmaceutical Co., LTD.
    Inventors: Yoichi Kawashima, Mitsuaki Kuwano
  • Procedure for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use
    Patent number: 5559104
    Abstract: A highly pure fraction of hyaluronic acid is disclosed which is non-inflammatory and avoids post-operative complications in ocular surgery. Also disclosed is a process for the preparation of hyaluronic acid characterized by converting hyaluronic acid into a corresponding quaternary ammonium salt and, following purification procedures, reconverting the quaternary ammonium salt into a sodium salt of hyaluronic acid.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: September 24, 1996
    Assignee: Fidia S.p.A.
    Inventors: Aurelio Romeo, Silvana Lorenzi
  • Drug delivery ophthalmic insert and method for preparing same
    Patent number: 5556633
    Abstract: A drug delivery ophthalmic insert prepared by forming a water soluble solid polymer into a paste by the addition of a small fixed amount of water, drying the paste and then sectioning the paste into a plurality of rod shaped inserts is provided. The insert is rendered suitable for prolonged and sustained delivery of medication to the eye since it is formed by the addition of a small amount of water and has a surface area less than about 3 mm.sup.2. Specific water soluble solid polymers which may be used include methylcellulose, hydroxyethyl cellulose, alginic acid and combinations thereof as well as mixtures of pilocarpine dispersed in methylcellulose and its combinations.
    Type: Grant
    Filed: April 28, 1993
    Date of Patent: September 17, 1996
    Inventors: Heskel M. Haddad, Spiro P. Loucas
  • Disinfecton formulations and methods using D-enantiomeric anti-microbial peptides
    Patent number: 5549894
    Abstract: A method for disinfecting a contact lens, includes the step of contacting the lens with an effective amount of at least one D-enantiomeric anti-microbial agent for a period of time sufficient to disinfect the lens. A proteolytic enzyme can be used in conjunction with the anti-microbial agent for combined disinfection and cleaning. Contact lens disinfecting compositions comprising a D-enantiomeric anti-microbial agent are also provided.
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: August 27, 1996
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Method for preparing a topical, aminocaproic acid containing ophthalmic gel
    Patent number: 5547680
    Abstract: A topical gel formulation containing aminocaproic acid prevents secondary hemorrhage following hyphema without the adverse side effects associated with systemically delivered aminocaproic acid. Of ten human patients treated with the formulation, none have experienced a secondary hemorrhage and none have experienced adverse side effects. The topical gel formulation is prepared by a process which ensures sterility, a pH compatible with conditions in the aqueous humor, and optimum consistency. A permeation enhancer such as proparacaine can be incorporated into the gel during formulation and be used to enhance the transport of aminocaproic acid across the corneal epithelium.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: August 20, 1996
    Assignees: Eastern Virginia Medical School, The Center for Innovative Technology
    Inventors: Patricia B. Williams, Earl R. Crouch, Jr.
  • Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
    Patent number: 5545617
    Abstract: A method of treating patients suffering from aberrant conjunctival goblet cell mucous secretion associated with a disorder of or injury to the eye is disclosed. The method, which is based on the discovery that conjunctival goblet cell mucous secretion is under the control of the autonomic nervous system, includes administering to an affected eye of a patient a neural system stimulus or inhibitor for sensory, parasympathetic or sympathetic nervous system function. Also disclosed are a therapeutic composition and an article of manufacture including the therapeutic composition useful for carrying out the method of the invention.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: August 13, 1996
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Darlene A. Dartt, Timothy L. Kessler
  • Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
    Patent number: 5540918
    Abstract: Certain anionic surfactants are used to enhance antimicrobial effectiveness in comfortable, sustained release ophthalmic compositions containing polyelectrolytes, such as carboxyvinyl polymers, polystyrene sulfonic acid polymers and cationic exchange resins, as well as at least one active ingredient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 30, 1996
    Assignee: Alcon Laboratories, Inc.
    Inventors: Ernesto J. Castillo, Yusuf Ali
  • Stabilization of aminosteroids for topical ophthalmic and other applications
    Patent number: 5538721
    Abstract: The invention provides methods for stabilizing amino-substituted steroid therapeutic agents in topical ophthalmic and other pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers; and methods for stabilizing and solubilizing amino-substituted steroid therapeutic agents in such pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers and amounts of selected cyclodextrin derivatives sufficient to at least partially solubilize the therapeutic agents. The cyclodextrin derivatives are selected from the group consisting of the hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of .beta.- and .gamma.-cyclodextrin. Stabilized and stabilized/solubilized pharmaceutical compositions adapted for various routes of administration are also described.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: July 23, 1996
    Assignee: InSite Vision Incorporated
    Inventors: John C. Babcock, Jon R. Polansky, Lyle M. Bowman, Sheng-Wan Tsao, Erwin C. C. Si, Santosh K. Chandrasekaran
  • Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
    Patent number: 5532227
    Abstract: A method for treating mammals suffering from excessive extracellular protein glycosylation which is associated with diabetes, scleroderma and progeria by administering to the mammal a tetracycline which effectively inhibits excessive protein glycosylation.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: July 2, 1996
    Assignee: The Research Foundation of State University of New York
    Inventors: Lorne M. Golub, Nungavarum S. Ramamurthy, Thomas F. McNamara, Maria E. Ryan
  • Method of retarding and ameliorating central nervous system and eye damage
    Patent number: 5527533
    Abstract: A method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering astaxanthin in a therapeutically-effective amount to prevent, retard or treat eye and central nervous system diseases or injuries, such as age-related macular degeneration and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: June 18, 1996
    Assignee: Board of Trustees of the University of Illinois
    Inventors: Mark O. M. Tso, Tim-Tak Lam
  • Dislocation of cataractous lens by enzymatic zonulolysis
    Patent number: 5527774
    Abstract: This invention is for a method of treating cataracts in eyes by couching or dislocating of the cataractous lens. It includes the steps of introducing a zonulolysis-causing substance into the interior of the eye adjacent to the cataractous lens in sufficient quantity and strength to produce zonulolysis of the lens zonules normally holding the lens of the eye in place. The zonulolysis-causing substance is maintained in said eye adjacent the zonules until zonulolysis occurs and said lens moves into the inferior cavity of the eye. Alphachymotrypsin is one form of zonulolysis-causing substance. That substance may be introduced through a clear portion of the cornea into the anterior chamber of the eye without rupturing the lens capsule. A quantity of aqueous may be removed from the anterior chamber before introducing the zonulolysis-causing substance.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: June 18, 1996
    Inventor: Louis J. Girard
  • Composition for treating ocular pain
    Patent number: 5525601
    Abstract: The invention relates to the use of a calcium channel blocking agent for the manufacture of a medicament for alleviatirtg pain, such as ocular pain. Particular calcium channel blocking agents that can be used in accordance with the invention are diltiazem, verapamil, nifedipine, nicardipine, and nimodipine.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: June 11, 1996
    Assignee: Universidad de Alicante
    Inventors: Carlos Belmonte-Martinez, Roberto Gallego-Fernandez, Miguel A. Pozo-Garcia, Juana Gallar-Martinez
  • Intraocular irrigating solution containing agent for controlling IOP
    Patent number: 5523316
    Abstract: Improved ophthalmic irrigating solutions are described. The solutions include one or more drugs for controlling intraocular pressure, an antioxidant/free radical scavenger, electrolytes, a cellular energy source, bicarbonate, and a buffer. Methods of using the solutions in connection with ophthalmic surgical procedures are also described.
    Type: Grant
    Filed: June 23, 1994
    Date of Patent: June 4, 1996
    Assignee: Alcon Laboratories, Inc.
    Inventors: Owen Gan, Rajni Jani, Ole J. Lorenzetti
  • Optic nerve health
    Patent number: 5523301
    Abstract: There is disclosed a method for maximizing the health of the optic nerve by application of topical .beta.-blockers to the eye. Maintaining or increasing retinal nerve fiber thickness has been found to have a link to the prevention of visual field loss and blindness.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: June 4, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Felix W. Amon, Bernard Schwartz
  • Topical ophthalmic pharmaceutical vehicles
    Patent number: 5521222
    Abstract: Ophthalmic pharmaceutical vehicles which become viscous on contacting the eye are disclosed. Ophthalmic compositions of the vehicle and a pharmaceutically active drug are also disclosed.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: May 28, 1996
    Assignee: Alcon Laboratories, Inc.
    Inventors: Yusuf Ali, Kenneth W. Reed
  • Ophthalmic use of muscarinic agonists having increased duration of activity
    Patent number: 5521210
    Abstract: A method for inducing prolonged pseudoaccommodation includes the instillation of an ophthalmic formulation into an eye for contracting the iris sphincter muscle, but not the ciliary muscle, in order to cause sphincter muscle contraction for a period of greater than about one hour per installation. The method further provides for the stabilization of an implanted intraocular lens immediately after surgery and for reducing glare following radial keratotomy.
    Type: Grant
    Filed: April 13, 1993
    Date of Patent: May 28, 1996
    Assignee: Allergan, Inc.
    Inventors: Elizabeth WoldeMussie, Roger F. Steinert, Guadalupe Ruiz
  • Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
    Patent number: 5520920
    Abstract: Certain anionic surfactants are used to enhance antimicrobial effectiveness in comfortable, sustained release ophthalmic compositions containing polyelectrolytes, such as carboxyvinyl polymers, polystyrene sulfonic acid polymers and cationic exchange resins, as well as at least one active ingredient.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: May 28, 1996
    Assignee: Alcon Laboratories, Inc.
    Inventors: Ernesto J. Castillo, Yusuf Ali
  • Nonirritating nonionic tissue cleaning compositions
    Patent number: 5518718
    Abstract: A nonirritating, nonionic detergent surfactant composition suitable for application to and cleaning of sensitive tissue, including periocular and ocular tissue, having a low cytotoxicity and high cleaning ability includes a principal nonionic surfactant and at least one auxiliary nonionic surfactant present in the surfactant composition in sufficient amounts to increase the cleaning ability of the principal nonionic surfactant.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: May 21, 1996
    Assignee: Allergan, Inc.
    Inventors: Shulin Ding, Thao T. Tran
  • Method for prophylaxis and treatment of myopia
    Patent number: 5519030
    Abstract: A method for the prophylaxis and treatment of myopia, comprising administering a compound of the formula ##STR1## wherein R is an alkyl, R.sup.1 is a hydrogen or an amino and R.sup.2 is a carboxyl or a tetrazole, or a salt thereof. The method for the prophylaxis and treatment of myopia of the present invention not only shows relaxing action on the ciliary smooth muscle of rabbit, but also shows superior effects of prevention and treatment of myopia of the patients on whom Mydrin-M, a conventional preparation for the prophylaxis and treatment of myopia, failed to have effects. In addition, the method does not involve a mydriatic response and can be advantageously used for the prophylaxis and treatment of myopia.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: May 21, 1996
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Toshiro Shigemitsu, Noriko Watanabe
  • Pharmaceutical compositions containing N-acetyl-cysteine derivatives useful for the treatment of cataract
    Patent number: 5519054
    Abstract: Pharmaceutical compositions for the treatment of cataract containing N-acetyl-L-cysteine derivatives of formula ##STR1## (wherein R and R.sub.1 have the meanings reported in the specification) are described.
    Type: Grant
    Filed: November 5, 1992
    Date of Patent: May 21, 1996
    Assignee: Zambon Group S.p.A.
    Inventors: Francesco Santangelo, Giorgio Bertolini, Franco Pellacini, Luciano Soldati, Annibale Gazzaniga, Cesare Casagrande
  • Nonaqueous fluorinated drug delivery vehicle suspensions
    Patent number: 5518731
    Abstract: Nonaqueous pharmaceutical compositions for use in aqueous physiological systems are disclosed comprising drug delivery vehicles suspended in nonaqueous perfluorocarbon or fluorinated silicone liquid carriers. The suspended drug delivery vehicles may be water labile or water stable and incorporate therapeutic or diagnostic compounds which remain stable and pharmaceutically effective for extended periods. The pharmaceutical compositions have improved bioavailability, are capable of low dose volume delivery, and do not leach the incorporated therapeutic or diagnostic compounds into the liquid carriers making them well suited for multi-dose packaging and administration.
    Type: Grant
    Filed: June 14, 1994
    Date of Patent: May 21, 1996
    Assignee: Allergan, Inc.
    Inventor: David L. Meadows
  • Topical cellulose pharmaceutical formulation
    Patent number: 5516808
    Abstract: The invention relates to an improved topical formulation, which is substantially free of an oil phase, and contains at least one antibiotic, purified water, and a gelling agent in an amount sufficient to form an aqueous gel.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: May 14, 1996
    Inventor: Assad S. Sawaya
  • Composition and method for reducing structural defects
    Patent number: 5516534
    Abstract: The invention provides a composition and method for reducing structural defects in metastable systems. Structural defects represent spaces or vacancies in the structural order of the metastable system, which can be restored to the predefect order through the use of structure makers. These structure makers will then occupy the space or vacancy of the defect, restoring the order of the system. Lithium ions are used as a preferred structure maker to reduce the structural defects that lead to cataract in a human lens.
    Type: Grant
    Filed: November 26, 1993
    Date of Patent: May 14, 1996
    Assignee: Rensselaer Polytechnic Institute
    Inventors: John Schroeder, Gillray L. Kandel
  • Fibronectin-containing ophthalmic solution, method of preserving an opthalmic solution, and methods of treatment of opthalmic wounds
    Patent number: 5514647
    Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: May 7, 1996
    Assignees: New York Blood Center, Inc., JCR Pharmaceuticals Co., Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Bernard Horowitz, Richard W. Shulman, Adrianne J. Setton, Toyohiko Nishimura, Yoichi Kawashima
  • Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials
    Patent number: 5512597
    Abstract: The invention relates to polymeric quaternary ammonium compounds which are useful as disinfectants and/or preservatives in ophthalmic compositions.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: April 30, 1996
    Assignee: Alcon Laboratories, Inc.
    Inventors: Evan P. Kyba, Joon S. Park
  • Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
    Patent number: 5510101
    Abstract: An ophthalmic pharmaceutical composition containing an association of N-acetyl-cysteine and polyvinylalcohol useful for the treatment of keratoconjunctivitis sicca.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: April 23, 1996
    Assignee: Zambon Group S.p.A.
    Inventors: Federico Stroppolo, Daniele Bonadeo, Francesco Tocchini, Annibale Gazzaniga